University Hospital Tuebingen

HepaRegeniX Secures €15 Million to Advance HRX-215 for Liver Regeneration

6 months ago

• HepaRegeniX has secured €15 million in a Series C round to advance the clinical development of HRX-215, a novel regenerative therapy for liver diseases. • HRX-215, a small molecule inhibitor of MKK4, aims to unlock the regenerative capacity of hepatocytes, potentially benefiting patients with liver tumors and those needing transplants. • The funding will support a Phase Ib clinical trial in the US and an international Phase IIa clinical trial to enhance liver recovery and prevent liver failure. • Dr. Linda Greenbaum, formerly of Novartis and Janssen R&D, joins HepaRegeniX as CMO to guide HRX-215 through Phase II trials and beyond.

HepaRegeniX Secures €15 Million to Advance HRX-215 for Liver Regeneration

8 months ago

• HepaRegeniX has raised €15 million in a Series C round to support clinical trials of HRX-215, a novel regenerative therapy for liver diseases. • The funding will facilitate a Phase Ib trial in the US and an international Phase IIa trial to assess HRX-215's ability to enhance liver recovery and prevent liver failure. • HRX-215, a small molecule inhibitor of MKK4, aims to unlock the regenerative capacity of hepatocytes, offering potential benefits in liver resection and transplantation. • Dr. Linda Greenbaum joins HepaRegeniX as CMO, bringing extensive experience in clinical development to guide HRX-215 through Phase II trials and beyond.

HepaRegeniX's HRX-215 Shows Promise in Liver Regeneration and Preventing Liver Failure

a year ago

• HepaRegeniX published clinical and preclinical results of HRX-215, a first-in-class MKK4 inhibitor, in Cell, demonstrating enhanced liver regeneration. • HRX-215 was found to be safe and well-tolerated in a Phase I study with healthy volunteers, paving the way for Phase II efficacy studies. • Preclinical data indicates HRX-215 boosts liver regeneration after partial hepatectomy and protects hepatocytes from cell death in acute liver injury models. • HRX-215 holds potential in oncological liver surgery and liver transplantation by preventing post-hepatectomy liver failure and enabling safer transplantation of smaller liver lobes.